BioMarin and Sarepta Therapeutics should be top growth plays in the next decade.
News & Analysis: BioMarin Pharmaceutical
BioMarin's stock is poised for big gains in 2020. Here's why.
BMRN earnings call for the period ending September 30, 2019.
BioMarin Pharmaceutical and Vertex Pharmaceuticals should prove to be outstanding growth vehicles in 2020 and beyond.
Long-term investors need to learn to stomach the ride.
BMRN earnings call for the period ending June 30, 2019.
Here's why this team of biotech experts are giddy about these stocks right now.
If you have some cash to put to work, you'll want to take a look at these three companies from the tech, drug, and industrial sectors.
The latest trial results for its hemophilia A gene therapy suggest it may eliminate or significantly reduce the need for weekly infusions.
Global Payments and Total Systems Services announced they plan to merge, and BioMarin reported results from a gene therapy trial.